Innate Pharma S.A.

Hello and welcome to the full year 2024 financial results and business update. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question, please press star 1 on your telephone keypad. I would now like to turn the conference over to Henry Wheeler, Vice President, Investor Relations and Communications. You may begin.

Thank you. Good morning, good afternoon, and welcome, everyone. This morning, Innate issued a press release for our full year 2024 business update and financial results. We look forward to highlighting the progress made during the year to date, as well as addressing future goals and milestones. The press release and today's presentation are both available on the IR section of our website. On slide two, before we start, I would like to remind you that we will be making forward-looking statements regarding the financial outlook in addition to the regulatory and product plan development. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. On slide three, quickly cover today's agenda. After an introduction from Jonathan Dickinson, our CEO, Yanis Morel, COO, will then discuss our preclinical ANCET platform and ADC updates. He'll then hand over to Sonia Quarantino, our Chief Medical Officer, to cover the clinical updates on the Gutamab IPH6501 and IPH4502, who will then hand to Frederick to cover the financials, our CFO, who will then hand to Jonathan, who will then wrap and close. Thank you. Jonathan, over to you.

Thank you, Henry. And good morning to our US participants and good afternoon in Europe. I'm happy to have the opportunity today to update you all on the latest developments at Innate Pharma. Turning to slide five, which illustrates our significant achievements, as we look back at 2024 and what we have achieved so far in 2025, I'm excited to share the progress made in advancing our innovative therapies and the key milestones we are expecting. IPH 65 remains a key focus for Innate, and we are pleased that the first patients were recruited into the phase one dose finding trial in the first half of 2024. This represented a critical step in the product's clinical development, and we are now focusing on progressing the trial rapidly through the next dosing cohorts so that we're able to share data towards the end of this year or early next year. We are highly committed to this program and optimistic about its potential to address unmet needs in oncology and potentially autoimmune diseases. We are thrilled with the progress of our Nectin-4 targeted ADC, IPH45, with the first patients dosed in January 2025, following the IND clearance in September 2024. This is an exciting milestone, and we are confident that this therapy will make a meaningful impact for patients. Our team is dedicated to moving this program forward rapidly and delivering the next generation of treatment for patients in need. Finally, we turn to lacutimab, which has made good progress recently on the path to commercialization. We are incredibly excited about the breakthrough therapy designation granted to lacutimab by the FDA. This brings lacutimab one step closer to a potential accelerated approval following the productive feedback received from FDA last year. This achievement is based on the strong data we have seen to date and reinforces the potential Lacutamab has to significantly help patients in need. As we continue our interactions with the FDA to finalize the confirmatory phase three in the coming months, we also look forward to sharing updated long-term follow-up data via publications at key scientific meetings. We also continue to look for the best path forward for Lakutamab with partnership discussions advancing well. We also continue to advance our early pipeline with the expectation to discover new ANKETs and ADCs. As we look ahead to 2025, we are confident that we are building momentum across our pipeline with significant achievements in IPH 65, IPH 45, and lakutamab. We remain dedicated to delivering breakthrough therapies to patients in need and are excited about the opportunities the next years will bring. As we reflect on our strategic focus for 2025, I want to take a moment to remind you of the updated strategic focus we shared during our presentation at the JPMorgan Healthcare Conference in January, which is illustrated on slide six. Our strategy is focused on three key growth pillars that we believe will drive long-term value for our innate pharma, our shareholders, and importantly, for patients. The first pillar is our NK cell engagers. The ANCAP platform continues to be a critical component of our strategy. We're advancing three key programs. IPH65, our CD20 ANCET, is currently in phase one. We're excited about IPH65's potential to address hematological malignancies and potentially autoimmune diseases. IPH61, our CD123 targeted ANCET, is progressing in phase two, with phase one data already presented by our partner, Sanofi. Fast-track designation was awarded for the treatment of acute myeloid leukemia. We believe that this asset has the potential to significantly impact patients' lives. IPH64, our BCMA ANCET, is in a phase one trial in myeloma in partnership with Sanofi and will be transitioned into autoimmune diseases. These three assets continue to bolster our leadership in NK cell engager therapies. The second strategic pillar is our antibody drug conjugates. We are particularly enthusiastic about IPH45, our nectin-4 targeted ADC. The IND cleared last year, and the first patients were dosed in January 2025. This differentiated topo-1 ADC targets high, moderate, and low overexpressing nectin-4 tumors. With Nectin-4 being overexpressed at varying levels in a range of large tumor types, IPH45's ability to bind low, moderate, and high-expressing tumors preclinically significantly expands the potential product opportunity. We also have IPH43, our MIC-AB targeted ADC program, in research, further advancing our capabilities in ADCs. The third pillar, is our current late-stage assets. We're committed to advancing our late-stage programs, particularly lacutimab. With positive phase two data and the FDA feedback on next steps, we are actively progressing partnership discussions. Lacutimab has also been awarded U.S. FDA Breakthrough Therapy designation, which underscores its potential in treating cesarean syndrome patients with high unmet medical need. Additionally, Monolizumab continues to progress well with AstraZeneca in the Pacific 9 phase 3 trial, and we're optimistic about its future potential. Slide 7 highlights our impressive pipeline. We are advancing a robust pipeline with eight innovative assets currently in the clinic. The highlights include our proprietary asset IPH65 for B-cell lymphomas. Our Sanofi-partnered assets, IPH6101 for AML and IPH6401 now for autoimmune diseases, and our proprietary ADC IPH45 targeting neptune foreign expressing tumors. In phase two, we have our proprietary KER3DL2 target antibodies, lacutamab for CTCL and PTCL. And finally, we have our AZ-partnered acid, monolizumab, which is being studied for neoadjuvant non-small cell lung cancer and in a phase three study for unresectable stage three non-small cell lung cancer. These assets demonstrate the productivity of our R&D organization and our commitment to delivering breakthrough treatments across a range of cancers. Slide eight illustrates our Q4 conference activity at CITSE and ASH last year. At the FITC meeting, we presented further preclinical data on our next generation CD20 targeting anket IPH65, as well as extensive preclinical data on our Nectin-4 targeted ADC IPH45. At ASH last year, we were pleased to present lacutimab quality of life and pruritus data in an oral presentation. This oral presentation showcased the consistency between the clinical and quality of life data and the important impact of Leukoleutomab on patient well-being. There was also a poster presentation of translational data from the TELEMAC trial. I would like to now pass the call to Yanis, who will review the preclinical rationale of our key strategic pillars in ANCETs and ADCs. Yanis.